NSE · Healthcare · Drug Manufacturers - Specialty & Generic
with an average price target of ₹466.00.
| Document | Date |
|---|---|
| Quarterly results · Q1 FY27 KILITCH DRUGS (INDIA) LIMITED – Q1 FY2026-27 RESULTS SUMMARY --- HEADLINE NUMBERS • Standalone Net Sales Q1 FY27: Rs 4,091.20 lakhs (down 43.1% YoY | 2026-08-13 |
| Annual report FY2026 KILITCH DRUGS (INDIA) LIMITED – SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Consolidated Total Income: ₹23,547.49 Lakh (FY 2025-26) vs. ₹19 | 2026-08-01 |
| Quarterly results · Q4 FY26 KILITCH DRUGS (INDIA) LIMITED - FINANCIAL SUMMARY HEADLINE NUMBERS • Net Sales/Income from Operations (FY 2025-26): Rs 18,857.43 lakhs vs Rs 18,158. | 2026-05-15 |
| Quarterly results · Q3 FY26 KILITCH DRUGS (INDIA) LTD — BOARD MEETING SUMMARY 11 FEBRUARY 2026 --- HEADLINE NUMBERS • Q3 FY2026 (Standalone): Net Sales INR 4,467 lakhs | Net P | 2026-02-11 |
| Quarterly results · Q2 FY26 KILITCH DRUGS (INDIA) LTD - H1 FY26 RESULTS SUMMARY HEADLINE NUMBERS • Profit After Tax (PAT): ₹10.30 crore in H1 FY26, up 18.1% YoY from ₹8.72 cror | 2025-11-14 |
| Annual report FY2025 KILITCH DRUGS (INDIA) LTD. - ANNUAL REPORT 2024-25 SUMMARY --- HEADLINE NUMBERS • Total Income: ₹19,530.26 Lakh (Standalone) | ₹20,947.91 Lakh (Con | 2025-09-01 |
| Quarterly results · Q1 FY26 KILITCH DRUGS (INDIA) LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • Standalone Q1 FY26 (Quarter ended 30 June 2025): Net Sales Rs 3,412.20 lakhs; Ne | 2025-08-13 |
| Quarterly results | 2025-02-11 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Bonus issue | 1 : 1 ex-date Mar 24, 2026 | 2026-03-24 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kilitch Drugs (India) Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.